Evidence map›Paper›PMID 28341698›Full record

ArticleG3 (Bethesda, Md.)2017

Desirée Villahermosa, Olaf Christensen, Karen Knapp, Oliver Fleck

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in G3 (Bethesda, Md.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. ACS omega · 2024
    Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Desirée VillahermosaNorth West Cancer Research Institute, School of Medical Sciences, Bangor University, LL57 2UW, UK.ORCID 0000-0003-4072-6159
Olaf ChristensenStrain Development LBPE38, Lonza, CH-3930 Visp, Switzerland.
Karen KnappNorth West Cancer Research Institute, School of Medical Sciences, Bangor University, LL57 2UW, UK.
Oliver FleckNorth West Cancer Research Institute, School of Medical Sciences, Bangor University, LL57 2UW, UK o.fleck@bangor.ac.uk.ORCID 0000-0003-0550-6513
Bangor University · GBLonza (Switzerland) · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Defective mismatch repair (MMR) in humans is associated with colon cancer and instability of microsatellites, that is, DNA sequences with one or several nucleotides repeated. Key factors of eukaryotic MMR are the heterodimers MutSα (Msh2-Msh6), which recognizes base-base mismatches and unpaired nucleotides in DNA, and MutLα (Mlh1-Pms1), which facilitates downstream steps. In addition, MutSβ (Msh2-Msh3) recognizes DNA loops of various sizes, although our previous data and the data presented here suggest that Msh3 of

Indexed as

DNA Mismatch RepairMicrosatellite RepeatsDNA-Binding ProteinsEndodeoxyribonucleasesGenomic InstabilityMutation RateMutL ProteinsMutS Homolog 3 ProteinRad51 RecombinaseSchizosaccharomycesSchizosaccharomyces pombe ProteinsDNA-Binding ProteinsEndodeoxyribonucleasesG-T mismatch-binding proteinMutL ProteinsMutS Homolog 3 ProteinRad2 protein, S pombeRad50 protein, S pombeRad51 RecombinaseRHP51 protein, S pombeSchizosaccharomyces pombe ProteinsFEN1homologous recombination repairmicrosatellite instabilitymismatch repairrepetitive DNA

Identifiers

PMID28341698
PMCPMC5427490
OpenAlexW2599475573

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.